Fuse VectorsFuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.
Tag Archive for: Venture Capital
The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).
Andera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.